New targeted approach to CRPC

Takeo Kosaka; Mototsugu Oya

doi:10.1007/978-981-10-7013-6_38

New targeted approach to CRPC

Takeo Kosaka, Mototsugu Oya

Department of Urology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.

Original language	English
Title of host publication	Hormone Therapy and Castration Resistance of Prostate Cancer
Publisher	Springer Singapore
Pages	375-385
Number of pages	11
ISBN (Electronic)	9789811070136
ISBN (Print)	9789811070129
DOIs	https://doi.org/10.1007/978-981-10-7013-6_38
Publication status	Published - 2018 May 11

Fingerprint

Keywords

AR signaling pathway
Cell-free DNA
Circulating tumor cells
CRPC
DNA repair pathway
Liquid biopsy
PI3K-PTEN-AKT-mTOR pathway
Precision medicine
WNT pathway

ASJC Scopus subject areas

Medicine(all)

Cite this

Kosaka, T., & Oya, M. (2018). New targeted approach to CRPC. In Hormone Therapy and Castration Resistance of Prostate Cancer (pp. 375-385). Springer Singapore. https://doi.org/10.1007/978-981-10-7013-6_38

@inbook{d550f1ab437443dd978803a200c03d65,

title = "New targeted approach to CRPC",

abstract = "Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.",

keywords = "AR signaling pathway, Cell-free DNA, Circulating tumor cells, CRPC, DNA repair pathway, Liquid biopsy, PI3K-PTEN-AKT-mTOR pathway, Precision medicine, WNT pathway",

author = "Takeo Kosaka and Mototsugu Oya",

year = "2018",

month = may,

day = "11",

doi = "10.1007/978-981-10-7013-6_38",

language = "English",

isbn = "9789811070129",

pages = "375--385",

booktitle = "Hormone Therapy and Castration Resistance of Prostate Cancer",

publisher = "Springer Singapore",

}

TY - CHAP

T1 - New targeted approach to CRPC

AU - Kosaka, Takeo

AU - Oya, Mototsugu

PY - 2018/5/11

Y1 - 2018/5/11

N2 - Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.

AB - Our understanding of the heterogeneity and genetic characteristics of CRPC demonstrates underlying their complexity, which has been thought to be associated with their intractability. Recent advance of integrative next generation sequencing unveiled the extensive mutational landscape of metastatic CRPC, many of which can be a targetable mutation and been linked to ongoing clinical trials. Molecular stratification of patient groups will clearly be critical to successful drug development and clinical trials from the view point of precision medicine. In this review, we discuss the potential of new targeted approach to impact the clinical management of CRPC.

KW - AR signaling pathway

KW - Cell-free DNA

KW - Circulating tumor cells

KW - CRPC

KW - DNA repair pathway

KW - Liquid biopsy

KW - PI3K-PTEN-AKT-mTOR pathway

KW - Precision medicine

KW - WNT pathway

UR - http://www.scopus.com/inward/record.url?scp=85053172302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053172302&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-7013-6_38

DO - 10.1007/978-981-10-7013-6_38

M3 - Chapter

AN - SCOPUS:85053172302

SN - 9789811070129

SP - 375

EP - 385

BT - Hormone Therapy and Castration Resistance of Prostate Cancer

PB - Springer Singapore

ER -

Access to Document

10.1007/978-981-10-7013-6_38